Veronika Dubrovskaya, MD
Gastroenterology · Brooklyn, NYNPI 1952559965
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Phathom Pharmaceuticals, Inc. accounts for 69.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $11,776 and has fallen 78.3% since, to $2,557 in 2025.
Across 200 payments — averaging $93.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$13K
- AbbVie$2K
- Ardelyx, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$618
- Takeda Pharmaceuticals U.S.A., Inc.$497
- Lilly USA, LLC$271
- plus $2K from 19 others
What the payments were for
- Consulting fees$1,2507%
- Speaking & faculty fees$10,75058%
- Travel & lodging$1,3277%
- Food & beverage$5,30428%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 19 | $12,900 |
| AbbVie(2 entities) | 59 | $1,549 |
| Ardelyx, Inc. | 3 | $1,299 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $618 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $497 |
| Lilly USA, LLC | 3 | $271 |
| Johnson & Johnson(2 entities) | 7 | $231 |
| Madrigal Pharmaceuticals | 3 | $176 |
| Pfizer | 8 | $163 |
| Bristol Myers Squibb | 4 | $104 |
| Medtronic | 1 | $103 |
| QOL Medical, LLC | 6 | $79 |
| UCB, Inc. | 3 | $78 |
| Gilead | 4 | $78 |
| Merck | 4 | $75 |
| Braintree Laboratories, Inc. | 4 | $68 |
| Endo Pharmaceuticals Inc. | 3 | $66 |
| Ironwood Pharmaceuticals, Inc | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Sanofi | 1 | $32 |
| Redhill Biopharma Inc. | 1 | $24 |
| Romark Laboratories, LC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,643 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 14 | $8,023 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 12 | $724 |
| Omeprazole | 54 | $672 |
| Famotidine | 36 | $215 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Brooklyn
- Sam MoskowitzBrooklyn$332K
- Jianjun LiBrooklyn$211K
- Nison BadalovBrooklyn$200K
- Kevin TinBrooklyn$168K
- Jonathan ErberBrooklyn$164K
- Rabin RahmaniBrooklyn$155K
- Kayane Hanna-HindyBrooklyn$151K
- Kadirawelpillai IswaraBrooklyn$148K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.